Kent u de chatbox al? chat met andere beleggers


Akebia Therapeutics (na fusie met Keryx)

Beleggen in aandelen beurs New York, Dow Jones, Nasdaq-100 en S&P500

believer
Forum elite
Forum elite
Berichten: 4842
Lid geworden op: 14 jan 2015 17:30
waarderingen: 4242
Contacteer:

Re: Akebia Therapeutics (na fusie met Keryx)

Bericht door believer »

Wk End 11/8 TRx 2.41k, NRx 893, TRx $2.68m
besportie liked last!





Volg Beursig.com op Twitter en Facebook

     


besportie
Forum veteraan
Forum veteraan
Berichten: 1196
Lid geworden op: 13 feb 2012 18:07
waarderingen: 329
Contacteer:

Re: Akebia Therapeutics (na fusie met Keryx)

Bericht door besportie »

"Piper Jaffray analyst price target for Akebia Therapeutics of $15 after Auryxia sales of $30.0M in Q3 missed his estimate by $2M. While some investors may be frustrated by yet another Auryxia miss, the big picture remains that Auryxia has a more important role as a vehicle for Akebia to establish a commercial platform from which to launch "the real value driver here - vadadusta," Raymond tells investors in a research note. As such, the analyst continues to recommend purchase of Akebia shares ahead of the Phase 3 data expected mid next year. He keeps an Overweight rating on the shares"
Aandelen: Soligenix 3.47$, Dare 1.18$, Euronav 8.07 eur, Inventiva 9.63 eur, Acacia 2.58 eur, Ontex 11.74 eur, Arrowhead 45.48$, Vaxart 7.39$, Ageas 37.10 eur / Turbo Long Ageas

besportie
Forum veteraan
Forum veteraan
Berichten: 1196
Lid geworden op: 13 feb 2012 18:07
waarderingen: 329
Contacteer:

Re: Akebia Therapeutics (na fusie met Keryx)

Bericht door besportie »

Artikel seeking alpha:

Summary
AKBA’s 3Q19 results showed no significant improvement in Auryxia sales or prescriptions.

The main source of value here continues to be vadadustat, which will have major data readouts in 2020.

With the probability of success for vadadustat unchanged, the lower entry point offers more upside than before.

On November 12 before the market opened, Akebia Therapeutics (NASDAQ:AKBA) reported 3Q19 results. As expected, we saw rather modest quarter-over-quarter (“QOQ”) sales and Rx growth from Auryxia, with the growth figures coming in at 3% and 5%, respectively. We continue to view Auryxia as simply a way to partially fund the more promising pipeline candidate, vadadustat.

Since our last article was published in July, the stock has come down about 25%, though, in our view, the news since then was either positive or non-material:

Earnings from 2Q19 (and now 3Q19) saw no meaningful development in terms of the outlook for Auryxia or the cash burn.
Follow-up data on November 9 was good - showing that vadadustat’s positive efficacy and safety data was sustained through to week 52, but these results were from the phase 3 trials being run in Japan. Given that the Japanese diet and lifestyle is on average healthier compared with other developed nations, investors seem to be waiting for the global phase 3 trials to read out in mid-2020 before rewarding AKBA with a sustained increase in the stock.
As of September 30, AKBA had $146M in cash and equivalents. Along with earnings, they co-announced that they have entered into a $100M loan agreement with Pharmakon Advisors, the investment manager of BioPharma Credit Funds. AKBA expects to draw $80M by the end of November and then can draw an additional $20M by the end of December. The loan bears interest at a rate of 3-month LIBOR plus 7.50%, so about 9.5% per year. This is not on the cheap side, but at least it eliminates the need for additional dilution as management says it will extend their cash runway into 2021 (so past the major data readouts expected by mid-2020).
The results from the two phase 3 trials in Japan show that (at least for that population) vadadustat is non-inferior in terms of efficacy and safety compared with darbepoetin alfa, an erythropoiesis stimulating agent (“ESA”). At the moment, injectable ESAs are the standard of care for patients with anemia due to chronic kidney disease (“CKD”), and have global sales of several billion dollars. AKBA is hoping that vadadustat, which is a once-daily oral treatment option, can disrupt this large market.

Additionally, AKBA’s lawsuit against the Centers for Medicare & Medicaid Services (“CMS”) might prove to be a lottery ticket if successful. AKBA is suing CMS over their decision to rescind Medicare Part D coverage of Auryxia when used for the treatment of iron deficiency anemia (“IDA”) in adult patients with CKD not on dialysis. The lawsuit also aims to reverse a related decision by CMS that implemented a prior authorization requirement for Auryxia when used for the control of serum phosphorus levels in adult patients with CKD on dialysis. Again, we assign no value to Auryxia currently, but a positive outcome from this lawsuit could provide additional upside.

While the stock has continued to drift, we see the commercial prospects of vadadustat, the crux of our long thesis, as unchanged. Coupled with the fact that the cash runway has been extended with the recently announced loan agreement, the lower entry point now offers even more upside to the bet with no additional risk on the chances of success for vadadustat.
Aandelen: Soligenix 3.47$, Dare 1.18$, Euronav 8.07 eur, Inventiva 9.63 eur, Acacia 2.58 eur, Ontex 11.74 eur, Arrowhead 45.48$, Vaxart 7.39$, Ageas 37.10 eur / Turbo Long Ageas

besportie
Forum veteraan
Forum veteraan
Berichten: 1196
Lid geworden op: 13 feb 2012 18:07
waarderingen: 329
Contacteer:

Re: Akebia Therapeutics (na fusie met Keryx)

Bericht door besportie »

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (AKBA) (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced its executives will participate in the following investor conferences:

Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019, at 8:30 a.m. ET in New York City, New York.
Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019, at 3:50 p.m. ET in Boston, Massachusetts.
Where applicable, a live webcast and replay of Akebia’s presentation will be available on the Company’s website at www.akebia.com.
believer liked last!
Aandelen: Soligenix 3.47$, Dare 1.18$, Euronav 8.07 eur, Inventiva 9.63 eur, Acacia 2.58 eur, Ontex 11.74 eur, Arrowhead 45.48$, Vaxart 7.39$, Ageas 37.10 eur / Turbo Long Ageas

besportie
Forum veteraan
Forum veteraan
Berichten: 1196
Lid geworden op: 13 feb 2012 18:07
waarderingen: 329
Contacteer:

Re: Akebia Therapeutics (na fusie met Keryx)

Bericht door besportie »

John Butler, the CEO of AKBA, bought 50,000 shares on November 21st at an average price of $3.44 - bron Yahoo Finance.

Dit lijkt mij toch een zeer positief teken ;)
believer liked last!
Aandelen: Soligenix 3.47$, Dare 1.18$, Euronav 8.07 eur, Inventiva 9.63 eur, Acacia 2.58 eur, Ontex 11.74 eur, Arrowhead 45.48$, Vaxart 7.39$, Ageas 37.10 eur / Turbo Long Ageas

believer
Forum elite
Forum elite
Berichten: 4842
Lid geworden op: 14 jan 2015 17:30
waarderingen: 4242
Contacteer:

Re: Akebia Therapeutics (na fusie met Keryx)

Bericht door believer »

Zeer positief artikel

https://seekingalpha.com/article/430868 ... make-break

Kunnen wel eens vertrokken zijn!

believer
Forum elite
Forum elite
Berichten: 4842
Lid geworden op: 14 jan 2015 17:30
waarderingen: 4242
Contacteer:

Re: Akebia Therapeutics (na fusie met Keryx)

Bericht door believer »

Overname op komst? Zou me niet verbazen

believer
Forum elite
Forum elite
Berichten: 4842
Lid geworden op: 14 jan 2015 17:30
waarderingen: 4242
Contacteer:

Re: Akebia Therapeutics (na fusie met Keryx)

Bericht door believer »

Shorters kiezen het hazenpad :D

believer
Forum elite
Forum elite
Berichten: 4842
Lid geworden op: 14 jan 2015 17:30
waarderingen: 4242
Contacteer:

Re: Akebia Therapeutics (na fusie met Keryx)

Bericht door believer »

besportie liked last!

besportie
Forum veteraan
Forum veteraan
Berichten: 1196
Lid geworden op: 13 feb 2012 18:07
waarderingen: 329
Contacteer:

Re: Akebia Therapeutics (na fusie met Keryx)

Bericht door besportie »

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tue December 3, 2019 4:06 PM|Business Wire|About: AKBA
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics (AKBA), Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted 14 newly-hired employees options to purchase an aggregate of 136,550 shares of Akebia’s common stock on November 29, 2019, as inducements material to each such employee’s entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $6.29 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of the company’s Inducement Award Program and a stock option agreement covering the grant.
believer liked last!
Aandelen: Soligenix 3.47$, Dare 1.18$, Euronav 8.07 eur, Inventiva 9.63 eur, Acacia 2.58 eur, Ontex 11.74 eur, Arrowhead 45.48$, Vaxart 7.39$, Ageas 37.10 eur / Turbo Long Ageas

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!


Plaats reactie